European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Page 13 of 13

10
11
12
13